二甲双胍维格列汀片治疗2型糖尿病合并非酒精性脂肪肝的临床效果研究

Study on the clinical effect of metformin vildagliptin tablets in the treatment of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

目的 分析二甲双胍维格列汀片治疗2型糖尿病合并非酒精性脂肪肝的临床效果。方法 70例2型糖尿病合并非酒精性脂肪肝患者,根据治疗方法的不同分为对照组及复合制剂组,每组35例。对照组患者采取二甲双胍治疗,复合制剂组采取二甲双胍维格列汀片治疗。比较两组治疗前后血脂、血糖、肝功能指标水平及治疗效果、不良反应发生情况。结果 治疗后,复合制剂组总胆固醇(4.04±0.14)mmol/L、低密度脂蛋白胆固醇(2.74±0.53)mmol/L、甘油三酯(1.32±0.51)mmol/L、空腹血糖(FBG)(7.21±1.81)mmol/L、餐后2 h血糖(2 h PBG)(9.01±2.71)mmol/L低于对照组的(5.07±0.15)、(3.82±0.61)、(1.81±0.41)、(9.21±2.41)、(11.12±5.29)mmol/L,高密度脂蛋白胆固醇(2.16±0.42)mmol/L高于对照组的(1.33±0.37)mmol/L,差异具有统计学意义(P<0.05)。治疗后,复合制剂组凝血酶原活动度(PTA)(45.13±12.16)%高于对照组的(38.15±10.20)%,天门冬氨酸氨基转移酶(AST)(40.13±2.13)U/L、总胆红素(TBIL)(181.67±3.52)μmol/L、谷丙转氨酶(ALT)(31.05±2.21)U/L低于对照组的(78.01±2.13)U/L、(251.21±7.45)μmol/L、(140.35±8.74)U/L,差异具有统计学意义(P<0.05)。复合制剂组治疗总有效率94.29%高于对照组的74.29%,差异具有统计学意义(P<0.05)。两组均未出现不良反应。结论 二甲双胍维格列汀片治疗2型糖尿病合并非酒精性脂肪肝的临床效果确切,可有效调节患者的血脂水平,促进患者血糖改善,并改善患者的肝功能,提高治疗的效果。

Objective To analyze the clinical effect of metformin vildagliptin tablets in the treatment of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Methods A total of 70 patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were divided into control group and compound preparation group according to different treatment methods, with 35 patients in each group. Patients in the control group were treated with metformin, and patients in the compound preparation group were treated with metformin vildagliptin tablets. The levels of blood lipids, blood glucose, liver function indexes before and after treatment,therapeutic effect, and occurrence of adverse reactions were compared between the two groups. Results After treatment, the total cholesterol(4.04±0.14) mmol/L, low density lipoprotein cholesterol(2.74±0.53) mmol/L,triglycerides(1.32±0.51) mmol/L, fasting blood glucose(FBG)(7.21±1.81) mmol/L, and 2 h postprandial blood glucose(2 h PBG)(9.01±2.71) mmol/L in the compound preparation group were lower than(5.07±0.15),(3.82±0.61),(1.81±0.41),(9.21±2.41), and(11.12±5.29) mmol/L in the control group;the high density lipoprotein cholesterol(2.16±0.42) mmol/L in the compound preparation group was higher than(1.33±0.37) mmol/L in the control group;the differences were statistically significant(P<0.05). After treatment, the prothrombin activity(PTA)(45.13±12.16)% in the compound preparation group was higher than(38.15±10.20)%in the control group;the aspartate aminotransferase(AST)(40.13±2.13) U/L, total bilirubin(TBIL)(181.67±3.52) μmol/L, and alanine aminotransferase(ALT)(31.05±2.21) U/L in the compound preparation group were lower than(78.01±2.13) U/L,(251.21±7.45) μmol/L, and(140.35±8.74) U/L in the control group;the differences were statistically significant(P<0.05). The total effective rate of treatment in the compound preparation group was 94.29%, which was higher than 74.29% in the control group, and the difference was statistically significant(P<0.05). No adverse reactions were observed in both groups. Conclusion The clinical effect of metformin vildagliptin tablets in the treatment of type 2 diabetes mellitus with non-alcoholic fatty liver disease is definite, which can effectively regulate the level of blood lipid, promote the improvement of blood glucose, and improve the liver function of patients, and improve the therapeutic effect.